Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
RA diagnosed according to the American College of Rheumatology (ACR)
You may not be if
Female patients who are pregnant, plan to become pregnant during the study, or are breastfeeding
Clinically significant abnormal ECG
History of anaphylactic reactions
Positive hepatitis C antibody or hepatitis B surface antigen
Positive serology for human immunodeficiency virus (HIV) by quantitative polymerase chain reaction
A history of an autoimmune disease other than RA (other than secondary Sjogren syndrome)
Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty syndrome
Malignancy, or prior malignancy, other than non-melanoma skin cancer, or cervical carcinoma in situ that has been resected
Recent administration of a live, attenuated vaccine, or anticipation that such a live attenuated vaccine will be required during the study or within 60 days after the last dose
Concomitant therapy with a biologic agent
Recent exposure to any investigational agent
Any current or recent signs or symptoms of infection requiring parenteral antibiotic administration
Hospitalization for a clinically relevant event within the 4 weeks prior to screening
